Belvedere M, Richiardi P, Savi M, Curtoni E S, Carbonara A O, Ceppellini R
Tissue Antigens. 1978 Feb;11(2):153-62. doi: 10.1111/j.1399-0039.1978.tb01241.x.
Appearance and evolution of anti-Da antibodies has been followed in eight volunteers immunized by whole blood transfusions or leukocyte intradermal injections form a single donor incompatible for HLA--A,--B,--C and--D specificities. Several unabsorbed bleedings from each recipient were studied against the specific immunizer with three different complement-dependent lymphocytotoxicity (CdL) techniques: (1) standard NIH CdL on total peripheral blood lymphocytes (PBL); (2) VII Workshop standard CdL technique on B cell-enriched suspensions; (3) beta2 microglobulin blanketing test ("bb" test) on B cells. Results obtained with the "bb" test were confirmed with platelet-absorbed sera. The "bb" and the absorbed sera allow discrimination between anti-Da and anti-HLA--A,--B,--C antibodies. Stage of appearance and evolution are rather similar for an anti-HLA--A,--B,--C and anti-Da. An early appearance of antibodies positive only against B cells is due to weak anti-HLA--A,--B antibodies which react better with B cells than with total PBL. Immunogenicity of Da antigens seems to be of the same order as HLA--A, and--B. In fact, Da reactivity was present in all eight recipients studied. These reactivities always segregated in familes with these HLA haplotypes. On a small panel of unrelated D-typed donors, three sera showed a significant positive association with D alleles.
对8名通过输注全血或皮内注射来自一名HLA - A、- B、- C和- D特异性不相合的单一供者的白细胞而免疫的志愿者,追踪了抗Da抗体的出现和演变情况。用三种不同的补体依赖淋巴细胞毒性(CdL)技术,针对特异性免疫原研究了每个受者的几次未吸收的出血样本:(1)对总外周血淋巴细胞(PBL)进行标准的美国国立卫生研究院(NIH)CdL检测;(2)对富含B细胞的悬液进行第七届研讨会标准CdL技术检测;(3)对B细胞进行β2微球蛋白覆盖试验(“bb”试验)。用血小板吸收血清证实了“bb”试验获得的结果。“bb”试验和吸收后的血清能够区分抗Da抗体和抗HLA - A、- B、- C抗体。抗HLA - A、- B、- C抗体和抗Da抗体的出现阶段及演变情况相当相似。仅对B细胞呈阳性的抗体早期出现,是由于弱的抗HLA - A、- B抗体,其与B细胞的反应比与总PBL的反应更好。Da抗原的免疫原性似乎与HLA - A和- B处于同一水平。事实上,在所研究的所有8名受者中均存在Da反应性。这些反应性总是与这些HLA单倍型在家族中分离。在一小批无关的D分型供者中,三份血清与D等位基因显示出显著的正相关。